Cover Image

Combinatorial latency reversal activity of inhibitor of apoptosis antagonists with mechanistically distinct classes of HIV latency reversal agents

Saved in:

Bibliographic Details
Main Authors:	Shane D. Falcinelli (Author), David M. Irlbeck (Author), Anne-Marie Turner (Author), Frances Potjewyd (Author), Lindsey I. James (Author), David M. Margolis (Author), Nancie M. Archin (Author), Richard M. Dunham (Author)
Format:	Book
Published:	Elsevier, 2019-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

SMAC mimetics are potent latency reversal agents with single agent and combination activity ex vivo
by: R.M. Dunham, et al.
Published: (2017)

SMAC mimetics reverse HIV latency by selective activation of the non-canonical NF-κB pathway
by: G.C. Sampey, et al.
Published: (2017)

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal
by: T.M. Mota, et al.
Published: (2016)

The SMAC mimetic AZD5582 reverses HIV latency as a single agent in resting primary CD4+ T cells
by: G. Sampey, et al.
Published: (2019)

Differential effects of HIV latency-reversing agents on T cell phenotype and function: implications for HIV cure
by: G. Clutton, et al.
Published: (2015)

Approaches to discover latency-reversing agents
Published: (2015)

Synergistic HIV latency reversal from an in vitro screen of epigenetic and kinase inhibitors
by: D. Irlbeck, et al.
Published: (2017)

PP 2.9 - 00125 Impact of latency reversal agents on estrogen receptor alpha gene and protein expression
by: C. Ceriani, et al.
Published: (2022)

HIV latency reversal using designed PKC modulators
by: M.D. Marsden, et al.
Published: (2017)

24 Thalidomide reverses latency of HIV-1 provirus
by: S. Samer, et al.
Published: (2016)

Optimisation of Smac mimetics as HIV-1 latency reversing agents
by: L. Pache, et al.
Published: (2019)

Identification of a promising new class of latency reversing agents
by: A. Gramatica, et al.
Published: (2017)

Integration site-independent enhancement of latency reversal by HIV-1 Nef
by: X.T. Kuang, et al.
Published: (2017)

Co-culture of T-cells with dendritic cells facilitates HIV latency in proliferating CD4+ T-cells: implications for the establishment and reversal of latency
by: N. Kumar, et al.
Published: (2015)

36 Dose-dependent effects of HDACi on T cell activation and HIV latency reversal
by: X.T. Kuang, et al.
Published: (2016)

Cleavage and polyadenylation specific factor 6 is required for HIV latency reversal
by: Y. Zheng, et al.
Published: (2019)

Evaluation of IAP/SMAC mimetics as latency reversal agents in primary cells and cytokine induction in in vivo models predictive of cytokine release
by: B. Howell, et al.
Published: (2019)

Future approaches to clearing the latent human immunodeficiency virus reservoir: Beyond latency reversal
by: Alexander M.L. Hayes
Published: (2020)

O3 Heme-arginate as a latency-reversing agent for HIV-1 cure
by: Michaela Madlenakova, et al.
Published: (2017)

The latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIV-infected rhesus macaques is potentiated by CD8a cell depletion
by: M. Mavigner, et al.
Published: (2019)

OP 2.8 - 00193 Enhancing PKC Modulator HIV Latency Reversing Agents
by: M. Marsden, et al.
Published: (2022)

Tissue-specific effects of latency-reversing agents on HIV transcriptional blocks in gut and blood
by: S. Telwatte, et al.
Published: (2019)

Evaluation of HIV latency reversal using designed PKC modulators in humanized BLT mice
by: M.D. Marsden, et al.
Published: (2015)

The contribution of memory CD4+ T cell subset phenotype to latency reversal efficiency
by: D.A. Kulpa, et al.
Published: (2017)

Novel use of alprazolam as a potential HIV-1 latency reversing agent
by: W. Elbezanti, et al.
Published: (2017)

PP 1.33 - 00167 Integrated single-cell multi-omic profiling of HIV latency reversal
by: A. Manickam, et al.
Published: (2022)

A theoretical framework to guide clinical trial design to estimate efficacies of latency-reversing agents
by: R. Ke, et al.
Published: (2015)

Induction of HIV from latency by a novel molecule
by: N.M. Archin, et al.
Published: (2015)

Validation of an unbiased screen method for the identification of secondary fungal metabolites reversing HIV-1 latency
by: M. Stoszko, et al.
Published: (2017)

Latency-reversing agents and cellular activation affect antigen processing in primary CD4 T cells
by: J. Boucau, et al.
Published: (2015)

PP 5.4 - 00184 Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents
by: L. Pache, et al.
Published: (2022)

Phorbol esters isolated from Croton megalobotrys reverse HIV latency ex vivo
by: I. Tietjen, et al.
Published: (2019)

Defining the Effects of PKC Modulator HIV Latency-Reversing Agents on Natural Killer Cells
by: Melanie Dimapasoc, et al.
Published: (2024)

Memory CD4+ T cell subsets show differential responses to HIV latency-reversing agents
by: D.A. Kulpa, et al.
Published: (2015)

CD8 depletion plus signaling of the non-canonical NF-kB pathway reverses latency in SIV-infected, ART-suppressed rhesus macaques
by: M. Mavigner, et al.
Published: (2019)

38 Small molecule inhibitors of BAF; a new family of compounds in HIV-1 latency reversal
by: E. De Crignis, et al.
Published: (2016)

No evidence of neuroaxonal injury following latency reversal with vorinostat and HIV-1 specific vaccination in the RIVER trial
by: J. Alagaratnam, et al.
Published: (2019)

In vitro analysis of different PKC agonists: latency reversal, T-cell activation, cytokine production and isoform selectivity
by: R. Barnard, et al.
Published: (2015)

Bioactive Compounds from <i>Euphorbia usambarica</i> Pax. with HIV-1 Latency Reversal Activity
by: Yu-Chi Tsai, et al.
Published: (2021)

Reactivation capacity by latency reversing agents ex vivo correlates with the size of the HIV-1 reservoir
by: Gilles Darcis, et al.
Published: (2016)